12:00 AM
 | 
Mar 01, 1993
 |  BioCentury  |  Finance

Analyst picks & changes

Amgen Inc.

Amgen Inc.'s announcement last week of sluggish U.S.

Neupogen

G-CSF sales for the quarter to date triggered a spate of analyst reappraisals on AMGN, just three weeks after lower-than-expected fourth quarter earnings sent analysts through the same exercise.

PaineWebber analyst Linda Miller lowered her rating on AMGN to "neutral" from "attractive"...

Read the full 273 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >